Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
Joong Sik Eom(Gachon University), Shinhye Cheon(Chungnam National University), Han Na Kim(Celltrion (South Korea)), Liliana Preoțescu(Virginia Commonwealth University), Young Rock Jang(Incheon Medical Center), Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Ilsung Chang, Oana Săndulescu(Carol Davila University of Medicine and Pharmacy), Mi Rim Kim(Celltrion (South Korea)), Da Rae Chung(Celltrion (South Korea)), Seul Gi Lee(University of Virginia), Sung Hyun Kim(Celltrion (South Korea)), Jin Yong Kim(Incheon Medical Center), Kim Ys(Seoul National University), Sang Joon Lee(Celltrion (South Korea)), Jee Hye Suh(Celltrion (South Korea))
Cited by 42
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Electrospinning of silk fibroin nanofibers and its effect on the adhesion and spreading of normal human keratinocytes and fibroblasts in vitro
|Biomaterials|2003|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k